De Novo DNA Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2M
- Investors
-
2
De Novo DNA General Information
Description
Developer of a genetic system software designed to make predictions to improve the performance of genetic systems. The company's platform offers to combine predictive biophysical models with computational optimization algorithms to design synthetic DNA sequences with well-predicted functions for various uses, enabling biotech researchers to rapidly engineer organisms with desired capabilities without the trial-and-error of iterative experimentation.
Contact Information
Website
www.denovodna.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
- 200 Innovation Boulevard
- Suite 239
- State College, PA 16803
- United States
+1 (415) 000-0000
De Novo DNA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Grant | 01-Jan-2018 | $2M | Completed | Profitable | ||
| 1. Accelerator/Incubator | 01-Apr-2012 | Completed | Startup |
De Novo DNA Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of a genetic system software designed to make predictions to improve the performance of genetic systems. The c
Biotechnology
State College, PA
3
As of 2021
0000000000
000000
mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000000000000
Portola Valley, CA
00
As of 0000
00.00
0000000000 0
00.00
000000
se cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
00000 0000000000 000
San Francisco, CA
000
As of 0000
00000
0.00
0000-00-00
00000000000
00000
Add Comparison
De Novo DNA Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TeselaGen Biotechnology | Venture Capital-Backed | Portola Valley, CA | 00 | 00.00 | 0000000000 0 | 00.00 |
| 000000000 | Venture Capital-Backed | San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
De Novo DNA Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Howard Salis | Founder & Chief Executive Officer |
De Novo DNA Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
De Novo DNA Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Defense Advanced Research Projects Agency | Government | 000 0000 | 000000 0 | ||
| Innovation Park at Penn State | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |